2
Announcements
Trials
Browse
Landscape
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pelvic Muscle Strength and Function
1
Osteonecrosis
1
Neoplasms
1
Multiple Myeloma
1
Cognition Disorders
1
Chemotherapy-Related Cognitive Impairment
1
Breast Neoplasms
1
Interventions
Dexamethasone
808
Bortezomib
446
Lenalidomide
430
Cyclophosphamide
336
Melphalan
250
Calcium Dobesilate
236
daratumumab
217
pomalidomide
201
carfilzomib
181
fludarabine phosphate
131
Thalidomide
121
fludarabine
118
Peripheral Blood Stem Cell Transplantation
117
Filgrastim
111
ixazomib
85
Mycophenolic Acid
85
Granulocyte Colony-Stimulating Factor
84
Busulfan
83
Whole-Body Irradiation
80
Tacrolimus
75
dexamethasone acetate
74
Cyclosporine
67
Prednisone
64
dexamethasone 21-phosphate
63
isatuximab
62
elotuzumab
60
auricularum
57
Antilymphocyte Serum
55
belantamab mafodotin
54
Etoposide
52
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Multiple Myeloma
×
Functional Status
×
Clear all
NCT05276622
2024-12-12
PaCE-MM
UNC Lineberger Comprehensive Cancer Center
Terminated
64 enrolled